Limits...
Safety and tolerability of regadenoson CMR.

Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE - Eur Heart J Cardiovasc Imaging (2014)

Bottom Line: Knowledge of adverse events associated with regadenoson perfusion cardiac magnetic resonance (CMR) and patient tolerability has implications for patient safety and staff training.We sought to assess the safety and tolerability of regadenoson stress CMR.Regadenoson CMR is well tolerated and can be performed safely with few adverse events.

View Article: PubMed Central - PubMed

Affiliation: Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive Bldg 10, Rm B1D416, MSC 1061, Bethesda, MD 20892-1061, USA Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA.

Show MeSH

Related in: MedlinePlus

Recruitment of subjects. AV, atrioventricular; CMR, cardiac magnetic resonance imaging.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4060784&req=5

JET278F2: Recruitment of subjects. AV, atrioventricular; CMR, cardiac magnetic resonance imaging.

Mentions: Seven hundred and eighty consecutive subjects were evaluated over a period of 2.6 years, but 27 patients were excluded because they did not receive regadenoson for various reasons (Figure 2). Thus, a total of 753 subjects [728 patients (median age 58 (IQR: 49–64, range 19–86), 44% female, 33% BMI ≥30 kg/m2, 20% DM and 25 normal volunteers (median age 21 (IQR: 20–23, range 18–48), 24% female)] were included in the final analysis. Two per cent of subjects (17 of 780) developed claustrophobia during the initial stages of the CMR exam and did not receive regadenoson nor complete the CMR exam—thereby accounting for 63% (17 of 27) of those excluded from the final analysis. Patient characteristics are summarized in Table 1.Table 1


Safety and tolerability of regadenoson CMR.

Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE - Eur Heart J Cardiovasc Imaging (2014)

Recruitment of subjects. AV, atrioventricular; CMR, cardiac magnetic resonance imaging.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4060784&req=5

JET278F2: Recruitment of subjects. AV, atrioventricular; CMR, cardiac magnetic resonance imaging.
Mentions: Seven hundred and eighty consecutive subjects were evaluated over a period of 2.6 years, but 27 patients were excluded because they did not receive regadenoson for various reasons (Figure 2). Thus, a total of 753 subjects [728 patients (median age 58 (IQR: 49–64, range 19–86), 44% female, 33% BMI ≥30 kg/m2, 20% DM and 25 normal volunteers (median age 21 (IQR: 20–23, range 18–48), 24% female)] were included in the final analysis. Two per cent of subjects (17 of 780) developed claustrophobia during the initial stages of the CMR exam and did not receive regadenoson nor complete the CMR exam—thereby accounting for 63% (17 of 27) of those excluded from the final analysis. Patient characteristics are summarized in Table 1.Table 1

Bottom Line: Knowledge of adverse events associated with regadenoson perfusion cardiac magnetic resonance (CMR) and patient tolerability has implications for patient safety and staff training.We sought to assess the safety and tolerability of regadenoson stress CMR.Regadenoson CMR is well tolerated and can be performed safely with few adverse events.

View Article: PubMed Central - PubMed

Affiliation: Cardiovascular and Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, 10 Center Drive Bldg 10, Rm B1D416, MSC 1061, Bethesda, MD 20892-1061, USA Division of Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA.

Show MeSH
Related in: MedlinePlus